互联网药学服务在卵巢癌患者口服PARP抑制剂中的应用  

Application of Internet Pharmaceutical Care in Patients with Ovarian Cancer Treated with Oral PARP Inhibitors

作　　者：刘慧[1] 谢婷婷[2] 杨柳 LIU Hui;XIE Ting-ting;YANG Liu(Department of Pharmacy,The First People's Hospital of Shangqiu City,Shangqiu 476100,China;Department of Pharmacy,Medical Security Center,Chinese PLA General Hospital,Beijing 100853,China;Department of Pharmacy,Shangshui People's Hospital,Zhoukou 466100,China)

机构地区：[1]商丘市第一人民医院药学部,商丘476100 [2]解放军总医院医疗保障中心药剂科,北京100853 [3]商水县人民医院药剂科,周口466100

出　　处：《中国合理用药探索》2024年第10期115-120,共6页Chinese Journal of Rational Drug Use

基　　金：商丘市第一人民医院院内重点支持项目(HS2022012)。

摘　　要：目的:探讨互联网药学服务在卵巢癌患者口服多腺苷二磷酸核糖聚合酶(PARP)抑制剂中的应用效果。方法:选取2021年9月~2022年3月某院收治的54例口服PARP抑制剂的卵巢癌患者作为研究对象,按照随机数字表法分为对照组和研究组,每组27例。对照组提供传统药学服务;研究组在传统药学服务基础上提供互联网药学服务。通过Morisky用药依从性问卷、自主设计的PARP抑制剂知识问卷和满意度问卷,了解患者用药依从性、用药知晓度和对互联网药学服务满意度,并比较两组患者不良反应发生情况。结果:研究组患者用药依从性和用药知晓度均优于对照组(P<0.05)。研究组因不良反应中止治疗者1例少于对照组3例(χ^(2)=1.067,P<0.05)。研究组27例患者中,对互联网药学服务满意17例,较满意9例,不满意1例。结论:在PARP抑制剂应用过程中,互联网药学服务可有效提高患者用药依从性、用药知晓度和用药安全性,且管理规范、操作简单、易被接受,可作为卵巢癌患者慢病管理的一种手段。Objective:To investigate the application effect of internet pharmaceutical care in patients with ovarian cancer treated with oral poly(ADP-ribose)polymerase(PARP)inhibitors.Methods:A total of 54 patients with ovarian cancer treated with oral PARP inhibitors from September 2021 to March 2022 were selected and divided into control group and study group by random number table,with 27 patients in each group.The control group was provided with traditional pharmaceutical care;The study group was provided with internet pharmaceutical care in addition to the traditional care.The Morisky medication adherence scale(MMAS),self-designed PARP inhibitor knowledge questionnaire and satisfaction questionnaire were used to understand patients'medication compliance,medication awareness and satisfaction with internet pharmaceutical care,and to compare the adverse reactions of the two groups of patients.Results:The medication compliance and knowledge of the patients were better in the study group than the control group(P<0.05).The number of patients with treatment interruption in the study group(1 patient)was smaller than the control group(3 patients)(χ^(2)=1.067,P<0.05).Among the 27 patients in the study group,17 were satisfied with the internet pharmaceutical care,9 were relatively satisfied,and 1 was dissatisfied.Conclusion:To the course of the use of PARP inhibitors,internet pharmaceutical care can bring effectively improved medication compliance,medication knowledge and medication safety.Besides,it is user-friendly and easily acceptable with standardized management.Hence,the internet pharmaceutical care may serve as a management tool for chronic diseases in patients with ovarian cancer.

关 键 词：互联网药学服务 PARP抑制剂 依从性 知晓度 安全性 

分 类 号：R95[医药卫生—药学]